Solvent Evaporation Technique Of Microencapsulation: A Systemic Review by Singh, Chitra et al.
International Journal of Advances in Pharmaceutical Analysis 
IJAPA Vol. 4 Issue 3 (2014) 96-104 
 
Corresponding Author*: 
 
singh11chits@gmail.com                                                                                96 
 
Solvent Evaporation Technique of Microencapsulation: A Systemic 
Review 
 
Chitra Singh
*1
, S. Purohit
2
, B. L. Pandey
2
 and Madhu Singh
2
 
 
1
Department of Pharmacology, IMS, BHU, Varanasi-221005, India 
2
Department of Pathology, Bundelkhand Govt. Ayurvedic college, Jhansi-284001, India 
 
Abstract 
Solvent evaporation is one of the most widely employed and investigated technique in pharmaceutical 
industries and research area for microencapsulation process. Microspheres are particles coated with a 
continuous film of polymeric material, having a diameter in range of 1 to 1000 μm and are widely used as drug 
carriers.  This technique provides a controlled drug release, having various clinical benefits. While initial lab 
scale experiments are carried out in simple beaker, stirrer setups, clinical trials and market introduction needs 
more sophisticated technologies, permitting economic robust, well-controllable and aseptic production of 
microspheres. In this review article our aim is to review and compile recent research work on solvent 
evaporation technique while focusing on different methods of above said technique and various factors 
affecting microencapsulation prepared by solvent evaporation technique. 
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1. Introduction 
Microspheres are defined as homogeneous, 
monolithic particles in the size range of about 1–1000 
µm and are widely used as drug carriers for controlled 
release. These systems have significant importance in 
biomedical applications. Administration of drugs in 
the form of microspheres usually improves the 
treatment by providing the localization of the active 
substance at the site of action and by prolonging 
release of drugs. Furthermore, sensitive drugs such as 
peptides and proteins may be protected against 
chemical and enzymatic degradation when entrapped 
in microspheres
1,2
. In drug delivery applications, poly 
(DL-lactide-co-glycolide) microspheres are being 
considered as the pharmaceutical products of the 
future. 
Controlled/targeted drug delivery using 
biodegradable polymeric carriers has gained 
increasing interest in the last two decades. In a 
majority of studies the lactide/glycolide homo- and 
copolymers have been used for drug delivery 
applications because they can be fabricated into a 
variety of morphologies, including films, rods, and 
microparticles, by compression molding, solvent 
casting, and solvent evaporation techniques
3-8
. For 
employment in the body, biodegradable polymers 
have an obvious advantage that after performing their 
function they degrade into nontoxic monomers, i.e., 
lactic and glycolic acids, thus avoiding the need for 
surgical removal. So, the risk of long-term toxicity or 
a probable immunological reaction when compared 
with nondegradable systems is also minimized. The 
release rate of an incorporated drug can be modulated 
by variation of the copolymer ratio and molecular 
weight. Gopferich reviewed polymer degradation 
mechanisms and mechanical properties extensively
9-
11
. An intelligent approach to therapeutics using drug 
carrier technology requires a detailed understanding 
of drug–carrier interactions with critical cellular and 
organ systems as well as an understanding of the 
limitations of the system with respect to formulation 
procedures and stability. 
A wide range of microencapsulation 
techniques have been developed to date
12
. Among 
them, solvent evaporation technique has become more 
useful as compared to other methods. In this method 
of microencapsulation, controlled particle sizes in the 
nano- to microsphere range can achieve high 
encapsulation materials and various conditions in 
order to achieve high encapsulation efficiency and a 
low residual solvent content. However, several 
process variables had been identified by researcher, 
which could affect the formulation of microsphere by 
solvent evaporation method, such as, type of solvent, 
volume of solvent, drug to polymer ratio, rate of 
solvent removal, effect of internal aqueous phase 
volume in case of solvent evaporation followed by 
multiple emulsion, effect of addition of buffer or salts 
to the internal or external phase, which can affect the 
size of microcapsules and also the release pattern of 
drug from microcapsules
13-16
.  The current review 
deals with the various methods, factors and other 
related aspects of solvent evaporation technique to 
formulate microencapsulation for the pharmaceutical 
use. 
 
2. The techniques of microencapsulation  
The technique of microencapsulation by 
solvent evaporation is widely applied in 
pharmaceutical industries to obtain the controlled 
release of drug. The obtained polymer microspheres 
with drug trapped inside can degrade and release the 
encapsulated drug slowly with a specific release 
profile. This controlled drug release has outstanding 
clinical benefits: reduction of dose frequency, more 
convenient and acceptable for patients and drug 
targeting to specific locations resulting in a higher 
efficiency
17,18
. There are different methods to use 
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microencapsulation by solvent evaporation technique. 
The choice of the method that will give rise to an 
efficient drug encapsulation depends on the 
hydrophilicity or the hydrophobicity of drug. Basic 
steps involved in solvent evaporation techniques are: 
2.1 Incorporation of pharmaceutical agents 
The polymer is dissolved in a suitable water 
immiscible solvent, and the pharmaceutical agent is 
directly added into the solution of polymeric-matrix 
materials by dissolution/dispersion in suitable 
solvents, or emulsification of aqueous solution of the 
pharmaceutical agents immiscible with the matrix-
material solution. For the preparation of solution or 
dispersion of pharmaceutical agents, impeller or static 
mixing, high speed-stator mixing or microfluidization 
techniques are generally used. 
2.2 Droplet formation 
This step determines the size of resulting 
microcapsules. The size of microcapsules affects the 
drug encapsulation efficiency and the rate of drug 
release. The following procedures are used in droplet 
formation: 
2.2.1 Stirring: The external phase is filled into a 
vessel and agitated by an impeller. The drug/matrix 
dispersion us then added, drop wise or all at once, 
under agitation at a speed sufficient to reach the 
desired droplet size
19
. 
2.2.2 Static mixing: Static mixer consists of baffles 
or other flow obstacles installed in a tube. The baffle 
arrangement repeatedly splits and recombines the 
stream of fluid passing through the tube. 
2.2.3 Extrusion: It involves feeding of drug/matrix 
dispersion through single or multichannel pathways 
directly into the continuous phase. When drug/ matrix 
dispersion leaves the pathways, discrete droplets are 
formed within the slow flowing continuous phase. In 
extrusion, flow is laminar, the droplets are formed at 
the site of introduction of drug/matrix dispersion into 
continuous phase, due to which there is no effect on 
size of droplets formed thereafter. On the contrary, 
static mixing relies mainly on turbulent flow, which 
constantly acts on the disperse phase and thus causes 
the size of the droplets to change over the whole 
length of the mixer. Therefore, extrusion is 
considered to allow for more uniform and better 
controlled microsphere sizes than static mixing. 
2.3 Solvent removal.  
Solvent removal can be achieved either by 
evaporation or by extraction. In both processes, the 
drug/matrix dispersion should be slightly soluble in 
the continuous phase, so that, partitioning into 
continuous phase can occur that leads to precipitation 
of the matrix material. The two ways of solvent 
removal can be performed: 
2.3.1 Solvent evaporation:  In this method, the 
capacity of the continuous phase is insufficient to 
dissolves the entire volume of disperse phase solvent. 
Thus, solvent evaporates from the surface of the 
dispersion to obtain hardened microcapsules. 
2.3.2 Solvent extraction: This is a two-step process. 
Firstly, the drug/matrix dispersion is mixed with a 
small quantity of continuous phase to yield desired 
size of droplets. Then secondly, further more 
continuous phase and/or additional extraction agents 
are added at an amount sufficient to absorb the entire 
solvent leaching from droplets of drug/matrix. This 
results into formation of solid microcapsules. 
2.3.3 Drying: Solidified microparticles from the 
continuous phase are by either filtration or 
centrifugation. Then the particles are rinsed with 
suitable liquids to remove adhering substance such as 
dispersion stabilizers or non-encapsulated drug. 
Finally, these microparticles are dried at elevated 
temperature or under reduced pressure to yield free 
flowing powder. The drying procedure removes not 
only continuous phase and wash fluid adhering to the 
microspheres’ surface but also traces of solvents and 
continuous phase from the interior of the particles. 
Thus, the conditions and rate of drying influence the 
amount of solvent and moisture residue
20
. 
Microsphere morphology and porosity as well as drug 
recrystallisation inside the spheres, and are therefore 
likely to affect the release behaviour of the final 
product. 
 
Fig. 1: Parallel installation of several static mixers for scale-up of microsphere  production
43
.. 
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Fig. 2: Microsphere preparation by electrostatic dripping
71
 
 
Fig. 3: Basic steps of microencapsulation by solvent evaporation. 
 
3. Different Techniques of micro- 
encapsulation 
3.1 Oil/Water emulsion followed by solvent 
evaporation: The drug substance is either dispersed 
or dissolved in the polymer/solvent system. Then it is 
added to the aqueous phase by continuous agitation. 
Agitation of the system is continued until the solvent 
partitions into the aqueous phase and is removed by 
evaporation. This process results in hardened 
microsphere which contains the active moiety that is 
drug. Several methods have been utilized to achieve 
dispersion of the oil phase in the continuous phase. 
The most common method is the use of a propeller 
type blade attached to a variable speed motor. Since 
high shear is used to produce the emulsion, the 
resultant product has a much smaller particle size than 
the emulsion produced by conventional agitation. 
Other method includes the use of a micro fluidizer to 
produce micro-emulsions, sonication and 
potentiometrics dispersion. 
A major problem with this technique is a 
poor encapsulation efficiency of moderately water 
soluble and water soluble compounds, which 
partitioned out from the organic dispersed phase into 
the aqueous continuous phase. Successfully 
entrapment of drug within the microspheres is thus 
highly dependent on solubility in the aqueous phase. 
Water soluble drugs (e.g. theophylline, caffeine and 
salicylic acid) could not be entrapped within the poly 
(lactic acid) (PLA) microsphere using an Oil/Water 
emulsion method, while drugs with low water 
solubility, such as Diazepam, Hydrocortisone and 
Progesterone were successfully retained within the 
microspheres. 
Table 1: Examples of hydrophobic and hydrophilic drugs encapsulated using solvent evaporation 
technique 
Hydrophobic drugs Name of drug Polymer References 
Cisplatin, 5-fluorouracil (anticancer agents) PLGA 
21,22  
Lidocaine (local anesthetics) PLGA 
PLA 
23,24   
 
Naltrexone, cyclazocine (narcotic antagonists) PLA 
PLA 
25,26,27  
 
Progesterone (hydrophobic steroids) PELA (PLA+ PEG) 
PLGA 
PLA 
28,29,30                                                                                      
 
Hydrophilic drugs Insulin 
 
O/O 
W/O/W  
O/W dispersion 
31   
32,33  
34     
Proteins O/O 
W/O/W 
35    
36,37,38  
Peptides 
 
co-solvent 
O/W dispersion  
O/O 
72,39 
72,40   
72     
 Vaccine W/O/W 
41.42,43                                                                             
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3.2 Water-oil-water multiple emulsion system 
This method for preparation of microsphere 
was reported to overcome the problem of low 
encapsulation efficiency of water-soluble drugs 
prepared by conventional w/o emulsion solvent 
evaporation method
44,45
. In this technique, polymer is 
dissolved in a suitable organic phase. In this organic 
phase, aqueous drug solution is emulsified using 
high-speed homogenizer operating around 15000-
20000 rpm for about 30 seconds to prepare w/o 
primary emulsion. This primary emulsion is added to 
external aqueous phase containing surfactant at 
homogenizer speed around 8000 rpm for 30 seconds 
and then stirred at 300 rpm for 3 hours at room 
temperature for permitting evaporation of organic 
solvent or it can be also performed under vacuum. 
The microcapsules obtained is collected by 
ultracentrifugation, filtration and then, lyophilized. 
Among them, lyophilisation decreases the burst 
effect. However, it may be change from drug to drug 
to obtain acceptable microcapsule size and drug 
release. 
3.3 Multiple emulsion of the Water/Oil/Oil or 
Water/Oil/Oil/Oil type 
Iwata and McGinity developed a multiple 
emulsion of the W/O/O/O type
46
. Multiphase 
microcapsules of PLGA containing water-in oil 
(W/O) emulsions were prepared by a multiple 
emulsion solvent evaporation techniques. Acetonitrile 
was used as the solvent for the polymer, and light 
mineral oil comprised the continuous phase for the 
encapsulation procedure in this investigation. Drug 
loading efficiencies of model water-soluble 
compounds was found 80 to 100 %. Scanning 
electron microscopy of transverse cross sections of 
the multiphase microsphere of W/O/O/O type 
belonged to the class of reservoir-type drug delivery 
devices. Utilization of this type of multiple emulsion 
system allows the encapsulation of the primary water 
in oil emulsion within a polymeric microsphere. The 
oil in the primary emulsion prevents contact between 
the internalized protein and the polymer/solvent 
system prevents possible denaturasation of the protein 
by the polymer or the solvent. Likewise, the 
possibility of polymeric degradation due to reactive 
proteins or drug compounds is also limited
46,47
. 
3.4 A modified water-in-oil-in-water (W/O/W) 
double emulsion solvent evaporation 
Taek Kyoung Kim et al has developed Gas 
foamed open porous biodegradable polymeric 
microsphere. Highly opened porous biodegradable 
polymeric microspheres were fabricated for use as 
injectable scaffold micro carriers for cell delivery. 
They modified water-in-oil-in-water (W/O/W) double 
emulsion solvent evaporation method for producing 
the microspheres .When an effervescent salt, 
ammonium bicarbonate is added in to the primary W1 
droplets, carbon dioxide and ammonia gas bubbles 
were spontaneously produced during the solvent 
evaporation process that stabilized the primary 
emulsion as well as created well inter-connected 
pores in the resultant microspheres. The porous 
microspheres fabricated under various gas foaming 
conditions were characterized. The size of the surface 
pores formed under the various gas foaming 
conditions became as large as 20μm in diameter. As 
the concentration of ammonium bicarbonate 
increased, the diameter which was sufficient enough 
for cell infiltration and seeding. These porous scaffold 
microspheres could be potentially utilized for 
cultivating cells in a suspension manner and for 
delivering the seeded cells to the tissue defect site in 
an injectable manner. 
3.1 Impact of various variables on 
microencapsulation via solvent evaporation 
technique 
3.1.1 Effect of polymer: Various polymers have their 
inherent quality. Therefore, the quality of the 
microencapsulation varies depending upon the 
polymer used. In pharmaceutical industry, 
biodegradable polymers are used for 
microencapsulation. Polymers used for 
microencapsulation of pharmaceuticals are: 
• Natural proteins like albumin, collagen, gelatin, 
fibrinogen, casein, fibrin, hayaluronic acid, etc. 
• Natural polysaccharides like starch, dextrin, alginic 
acid, chitin, chitosan, etc. 
• Semisynthetic polysaccharides like ethyl cellulose, 
hydroxyl ethylcellulose, hydroxyl propylcellulose, 
methyl cellulose, hydroxyl propyle ethylcellulose, etc. 
• Synthetic polymers like poly (lactic acid), poly 
(lactic/glycolic acid), poly (_-hydroxybutyric acid), 
poly orthoester, poly alkyl cyanoarylate, various 
grades of Eudragit, etc 
Owing to the excellent biocompatibility property of 
the biodegradable polyesters poly (lactic \ acid) 
(PLA) and poly (lactic-co-glycolic acid) (PLGA), 
these are the most widely used biomaterials for the 
microencapsulation of therapeutics and antigens
48,49
. 
Ethyl cellulose, cellulose acetate, cellulose acetate 
phthalate (CAP), cellulose acetate butyrate (CAB) 
and various grades of Eudragit are also used for the 
microencapsulation of various drugs using solvent 
evaporation technique and found suitable in terms of 
ease of preparation, size and better controlled release 
drug delivery
50-57
. Moreover, these polymers are 
comparatively low-cost than PLA and PLGA. The 
molecular weight of polymers used in 
microencapsulation using solvent evaporation 
technique is also another important factor. Fu et al 
have developed a long acting injectable Huperzine A-
PLGA microsphere for the chronic therapy of 
Alzheimer’s disease. These microspheres were 
prepared by solvent evaporation method. It was 
observed that the PLGA 15000 microspheres 
possessed a smooth and regular particle size of 
around 50 μm. The drug encapsulation percentage of 
microsphere prepared from PLGA 15000, 20,000, and 
30,000 were 62.75 %, 27.52 % and 16.63 %, 
respectively
58
. The drug encapsulation efficiency of 
these microspheres was found increased with the 
increment in molecular weight of polymer (here, 
PLGA) due to stronger barrier characteristics of high 
molecular weight polymers. In this study, they have 
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also found an increment of drug encapsulation 
efficiency in these microspheres as the polymer 
concentration was increased in oily phase, and poly 
vinyl alcohol (PVA) concentration decreased in 
aqueous phase. In another investigation, Uchida et al., 
have used different PLGA and they have experienced 
the same as previous investigation stated above. They 
found highest ovalbumin loading in PLGA (85:15) 
than other PLGA grades
59
. 
3.1.2 Effect of drug to polymer ratio: For the 
entrapment of bovine serum albumin (BSA) into poly 
(methyl methacrylate)(PMMA) microspheres, a ratio 
of less than 1:10 was suggested to yield 
proteinloadings of >80% A higher load of bioactive 
material is likely to decrease the encapsulation 
efficiencies of proteins and peptides in PLGA and 
increase the 24 hrs (―burst‖) drug release In some 
cases, increase in drug content, increases the 
entrapment efficiency e.g. an increase in entrapment 
efficiency ovalbumin (ova) from 40% to 98% with an 
increase in actual ova content from 7% to 16%(w/w). 
Cavalier et al (1986) studied the preparation of PLA 
microcapsules containing hydrocortisone using 
polyvinyl alcohol (PVA) (partially hydrolyzed 88%) 
and methyl cellulose (400cps and 10cps grades) as 
colloidal emulsifiers. They reported that when the 
drug/polymer ratio was less than 0.4, microcapsules 
could be prepared using PVA (0.1%in water) only 
and in regular dimensions. But when this ratio 
exceeded 0.6, irregular and large aggregated 
microcapsules were formed due to the formation of 
unstable emulsion. 
Effects of organic solvents. For the 
technique of microencapsulation by solvent 
evaporation, a suitable solvent should meet the 
following criteria: 
(1) Being able to dissolve the chosen polymer; 
(2) Being poorly soluble in the continuous phase; 
(3) Having a high volatility and a low boiling point; 
(4) Having low toxicity 
 
Chloroform was frequently used before, but 
due to its toxicity and low vapour pressure, it is 
gradually replaced by methylene chloride. Methylene 
chloride is the most common solvent for the 
encapsulation using solvent evaporation technique 
because of its high volatility, low boiling point and 
high immiscibility with water. Its high saturated 
vapour pressure compared to other solvents (at least 
two times higher) promises a high solvent evaporation 
rate, which shortens the duration of fabrication of 
microspheres. However this solvent is confirmed 
carcinogenic according to EPA (Environmental 
Protection Agency) data and the researchers are 
making great efforts to find less toxic replacements. 
Ethyl acetate shows promising potential as a less 
toxic substitute of methylene chloride. But due to the 
partial miscibility of ethyl acetate in water (4.5 times 
higher than that of methylene chloride), microspheres 
cannot form if the dispersed phase is introduced 
directly into the continuous phase. The sudden 
extraction of a big quantity of ethyl acetate from the 
dispersed phase makes the polymer precipitate into 
fibre-like agglomerates
60
. To resolve this problem 
created by the miscibility of solvent with water, three 
methods can be used: the aqueous solution is pre-
saturated with solvent
61
; the dispersed phase is first 
emulsified in a little quantity of aqueous solution; 
after the formation of drops this emulsion is poured 
into a large quantity of aqueous solution
60
; the 
dispersed phase is emulsified in a little quantity of 
aqueous solution, the solution is agitated and the 
solvent evaporates leading to solidification of 
microspheres
62
. Using these methods, the 
microspheres are manufactured successfully with 
ethyl acetate. However, the microspheres prepared by 
methylene chloride are spherical and more uniform, 
while the use of ethyl acetate results in particles 
which appear to be partly collapsed
63
.  
The drug encapsulation efficiency reduces 
significantly compared to the microspheres made by 
methylene chloride. The author assumed that it is due 
to the high solubility of ethyl acetate in water, leading 
to the loss of drug. Based on this assumption, we 
make a further assumption that it is due to two main 
causes: (1) more drug is entrained into the continuous 
phase by the higher mass flux of solvent, which is 
driven by the diffusion from the dispersed phase into 
the continuous phase; (2) the big quantity of solvent 
present in the continuous phase increases the 
solubility of drug in the continuous phase, facilitating 
the diffusion of drug into the continuous phase. Ethyl 
formate shows also interesting results. Sah has 
succeeded in manufacturing microspheres of PLGA 
with ethyl formate
64
. He observed that the evaporation 
rate of ethyl formate in water was 2.1 times faster 
than that of methylene chloride although ethyl 
formate possesses a lower vapour pressure and a 
higher boiling point according to the authors. This 
phenomenon is explained by the fact that more 
molecules of ethyl formate are exposed to the air–
liquid interface because of its higher water solubility. 
His work proved that water immiscibility of a solvent 
is not an absolute prerequisite for making an 
emulsion. More experiments have to be carried out to 
confirm the promising use of ethyl formate. In 
summary, less toxic solvents have been tested and 
show a promising future. But there are not enough 
results to compare the quality of microspheres 
prepared by different solvents. Methylene chloride is 
still the most used solvent because it evaporates fast, 
shows high drug encapsulation efficiency and 
produces microspheres with spherical and more 
uniform form. 
3.1.3 Effect of solubility of drug in continuous 
phase: Drug loss may occur to continuous phase 
while the dispersed phase remains in a transitional, 
semi-solid state. If the solubility of drug in the 
continuous phase is higher than in the dispersed 
phase, then the drug may easily diffuse into the 
continuous phase during this stage. It was observed 
that the encapsulation efficiency of quinidine sulphate 
was 40 times higher in alkaline (pH-12) continuous 
phase than in the neutral (pH-7) continuous phase 
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because quinidine sulphate is insoluble in alkaline pH 
whereas very soluble in neutral pH. 
3.1.4 Rate of solvent removal: The rate of solvent 
removal from microsphere prepared by the solvent 
evaporation method has a great impact on the 
physiochemical properties of the microsphere. 
Izumikawa et al observed a significant difference in 
physical property and drug release profile between 
progesterone loaded PLA microsphere prepared by 
either reduced pressure solvent evaporation or a 
solvent evaporation method under atmospheric 
conditions. Encapsulation efficiency was greater for 
microsphere prepared by the reduced pressure solvent 
extraction method (RSE) than for those prepared by 
the atmospheric solvent evaporation (ASE). When 
surface morphology of these microspheres were 
studied under scanning election microscopy, it 
indicated a porous and rough surface for RSE 
microsphere. The ASE microsphere exhibited peaks 
due to crystalline progesterone in addition to peaks 
due to crystalline poly (l-lactide) PLA. The RSF 
microspheres displayed no such peaks due to 
crystalline PLA which suggest that the PLA was 
present in the amorphous state. Additionally, the RSE 
microsphere exhibited no peaks corresponding to 
crystalline progesterone which indicated that drug 
was dispersed in an amorphous polymer network. It 
was assumed that the solvent removal under the 
reduced pressure occurred too rapidly for the polymer 
to crystallize. Drug release from the microsphere was 
found to be significantly influenced by the 
crystallinity of the polymer matrixes, the drug release 
rate increased with the drug loading for both types of 
microsphere. For the ASE microsphere, there was a 
rapid release in the initial stage, and the release rate 
was much greater than that of the RSE microspheres. 
The ideal rate of solvent removal depends on a variety 
of factors like the types of matrix material used, drug 
and solvent as well as the desired drug release profile 
of microsphere. Like, fast microsphere solidification 
will be preferred if the drug easily partition into the 
continuous phase, whereas slow solidification favours 
denser over more porous microsphere, affecting the 
drug release. 
3.1.5 Effect of preparation temperature: Yang et 
al., have studied the influence of preparation 
temperature on the various characteristics and release 
profile of PLGA microspheres, prepared using solvent 
evaporation technique
65
. They have studied the 
formation of PLGA microspheres in varying 
temperature (4-42°C). The PLGA microspheres tend 
to be larger when prepared at higher temperature (38 
and 42°C), showed wider size distributions, and 
decreased particle density as compared to 
microsphere prepared at lower temperature (4-33°C). 
The morphology of the particle interior (honeycomb-
like) and drug encapsulation efficiency (53 % to 63 
%) were unaffected by the preparation temperature. In 
case of PGLAPEG blend, drug encapsulation 
efficiency was unaffected with a minimum efficiency 
of (15 % to 63 %) were unaffected by the preparation 
temperature, whereas in case of PLGA-PEG blend, 
drug encapsulation efficiency was affected with a 
minimum efficiency of 15 % at 22°C, which steadily 
got improved (around 52 %) for lower and higher 
temperatures. Microspheres prepared at high 
temperature were found to be a uniform internal pore 
distribution and a very thin dense skin layer, whereas 
microsphere prepared at lower temperature showed a 
thick but porous skin layer and bigger pores in the 
middle of the sphere. Microspheres formed at 33°C 
experienced the highest initial burst release. In term 
of in vitro drug release, microspheres fabricated at 
low temperature (5, 15, 22°C) exhibited similar 
steady drug release rates. However, microspheres 
formed at higher temperature exhibited low release 
rates after their initial drug release. 
3.1.6 Effect of interaction between drug and 
polymer: The interaction between drug encapsulated 
and polymer can change in drug encapsulation 
efficiency. The interaction between drug and polymer 
may be hydrophilic or hydrophobic interaction. In 
case of hydrophilic or ionic interaction, the drug is 
best encapsulated in polymers containing free 
carboxylic end groups. 
In case of hydrophobic interaction, relatively 
hydrophobic end capped polymers are more effective 
in increasing encapsulation efficiency
66
. On the other 
side, such interaction between drug and polymer may 
limit the protein release from the microsphere
67
. In 
certain cases, co-encapsulated excipients can mediate 
interaction between protein and polymer. 
Encapsulation efficiency of tetanus toxoid in PLGA 
increased, when gamma hydroxyl propyl cyclodextrin 
(g-HPCD) were incorporated. It is supposed that the 
g-HPCD increased the interaction by involving amino 
acid side group of the toxoid into its cavity and 
simultaneously interacting with PLGA through 
Vander Waal and hydrogen bonding forces
68
. 
3.1.7 Effect of buffer or added salt: On considering 
the properties of somatostatin acetate containing 
polylactide microsphere, Herrmann and Bodmeier 
prepared microsphere for encapsulation efficiency, 
drug release, and morphological properties. Addition 
of buffers or salts to the internal aqueous phase 
resulted in the formation of a dense and homogenous 
polymer matrix. Drug release profile consisted of a 
rapid drug release phase followed by a slow release 
phase. This pattern is consistent with many matrix-
type drug delivery systems. In this the drug release 
profile can be divided into two phase; a rapid release 
phase representing the release of the peptide by 
diffusion through the polymer matrix. Lower 
encapsulation efficiencies were obtained with the 
more porous microspheres. Addition of buffer salts to 
the internal aqueous phase promoted an influx of 
water from the external phase due to a difference in 
osmotic pressure. This resulted in a more porous 
microsphere structure, faster drug release, and lower 
encapsulation efficiency. Ahmad Al-Maaieh and 
Douglas R. Flanagan found increase in microsphere 
drug loading by changing the aqueous solubility of 
both the drug and the organic solvent DCM. 
Quinidine sulfate solubility was depressed by either a 
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common ion effect (Na2S04) or by formation of new, 
less soluble drug salts (e.g., bromide, perchlorate, and 
thiocyanate). Inorganic salts depress DCM aqueous 
solubility to different extents as described by the 
Hofmeister series. NaClO4 and NaSCN depressed 
drug solubility to the highest extent, resulting in 
microspheres with high drug loading (e.g.,>90%). 
Other salts such as Na2SO4 did not depress quinidine 
sulphate solubility to the same extent and did not 
improve loading. The use of a cosolvent (ethanol) in 
the organic phase was found to improve drug loading 
and make uniform drug distribution with smooth 
release profiles. 
3.1.8 Effect of internal aqueous phase volume on 
loading capacity: Comparatively with large volume 
of internal aqueous phase (500 μl or 1000 μl), 
decrease in loading efficiency of ovalbumin was 
occurred
68,69
. While using smaller of internal phase of 
50 μl, high drug loading efficiency was observed. 
With the increment of internal phase volume, thin 
layer of phase (methylene chloride) might be formed, 
which could act as a barrier for diffusion of drug to 
the external aqueous phase. With the thinner organic 
phase, the more diffusion and probability of diffusion 
from internal phase to external phase was observed, 
which could lower the drug loading efficiency. So, 
small internal phase volume was found to be 
beneficial to get high drug loading
70
. 
3.1.9 Effect of external aqueous phase volume on 
loading capacity: Parikh et al., have found that an 
increase in the volume of the external phase of the 
secondary emulsion lead to a decrease in the particle 
size of microspheres
69
. The droplet size of the 
secondary emulsion may decrease because of a 
decrease in the frequency of collision of droplets with 
an increase in the volume of the external phase of the 
secondary emulsion. The decrease in the particle size 
of microspheres associated with an increase in the 
volume of the external phase of the secondary 
emulsion may attribute to a decrease in the secondary 
emulsion. 
3.1.10 Effect of stirring speed: During droplet 
formation step, the stirring of impeller or baffles used, 
determines the size of microsphere. Increasing the 
mixing speed generally, results in decreased 
microsphere mean size
71
. In the investigation by our 
group, we found that increased stirring speed 
produced smaller sized microparticles using 
emulsification solvent evaporation technique. This 
phenomenon strongly supports the idea that the high 
stirring speed could provide high shearing force 
needed to breakdown the drug-polymer droplets into 
smaller particles 
53
. The drug release from these 
smaller microparticles prepared with high stirring 
speed was found faster than that lower speed. The 
reduction of mean particle size of microparticles 
could facilitate higher rate of drug diffusion from 
larger surface area provided by the smaller 
microparticles. 
 
 
4. Conclusion 
Solvent evaporation techniques offer a 
versatile, easy, and practical method for the 
manufacture of biodegradable microspheres. This 
technique makes possible the entrapment of a wide 
range of drugs having different physical properties 
and solubility characteristics. The properties of 
materials and the processing aspects strongly 
influence the properties of microspheres and the 
resultant controlled release rate. Because of 
outstanding biocompatibility and biodegradability 
PLGA polymers are frequently used as most 
promising synthetic biodegradable polymeric carrier. 
Most widely used solvent is methylene chloride 
owing to its high volatility and capacity to dissolve 
most polymers. However due to its carcinogenic 
nature, efforts are being made to replace it and 
substitutes such as ethyl acetate and ethyl formate 
give promising results. The microspheres with the 
desired properties are obtained by various operating 
variables such as organic solvent, rate of solvent 
removal, and amount of organic solvent or drug 
solubility, drug to polymer ratio, partition coefficient, 
polymer composition and molecular weight, and 
method of method of manufacture etc. All these 
factors play an important role in the development of 
successful controlled release polymeric microspheres 
containing drugs. Based on previous studies it was 
found that during microencapsulation of peptides and 
proteins; mechanical processing, solvents interaction, 
pH of the medium must be taken into account while 
processing and storage. These are the conditions that 
can result in degradation, denaturation and 
conformational changes in peptides and proteins; 
rendering them inactive. Sometimes certain proteins 
may prematurely degrade the polymer used in 
microencapsulation. In response to these concerns, 
innovative methods of microsphere production, such 
as multiple emulsion following solvent evaporation 
techniques have been investigated. After reviewing 
different aspects of solvent evaporation technique; 
overall summary is that there is necessity of designing 
formulations with desired release rate and drug 
entrapment efficiency. 
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